Edition:
United States

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

19.16USD
4:00pm EDT
Change (% chg)

$0.15 (+0.79%)
Prev Close
$19.01
Open
$19.18
Day's High
$19.18
Day's Low
$18.57
Volume
16,777
Avg. Vol
38,551
52-wk High
$21.01
52-wk Low
$12.65

Chart for

About

Mersana Therapeutics, Inc. is a biotechnology company. The Company is focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design... (more)

Overall

Beta: --
Market Cap(Mil.): $424.26
Shares Outstanding(Mil.): 22.90
Dividend: --
Yield (%): --

Financials

  MRSN.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -1.89 -- --
ROI: -57.97 -8.07 12.63
ROE: -- -10.87 14.50

BRIEF-Mersana Therapeutics Reports Q1 Loss Per Share $0.54

* MERSANA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

May 14 2018

BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61

* MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

Mar 28 2018

BRIEF-Mersana Appoints David Spellman As Chief Financial Officer

* MERSANA APPOINTS DAVID A. SPELLMAN AS CHIEF FINANCIAL OFFICER

Mar 12 2018

BRIEF-Mersana Announces First Patient Dosed With XMT-1536 In Phase 1 Study In Patients With NaPi2b-Expressing Tumors

* MERSANA ANNOUNCES FIRST PATIENT DOSED WITH XMT-1536 IN PHASE 1 STUDY IN PATIENTS WITH NAPI2B-EXPRESSING TUMORS Source text for Eikon: Further company coverage:

Dec 12 2017

Earnings vs. Estimates